Chinese biotech firm Acastle has achieved a historic milestone in oncology by becoming the first China-originated innovative drug to be presented at the prestigious plenary session of the American Society of Clinical Oncology annual meeting in Chicago. The plenary session is typically reserved for practice-changing results, and the data presented over the weekend has sent shockwaves through both the medical and investor communities, with Acastle shares surging 10 percent in pre-market trading on Monday.
The results from the Harmony 6 trial showed that ivonescimab, a bispecific antibody targeting both PD-1 and VEGF pathways, achieved a hazard ratio of 0.66 for overall survival in patients with squamous lung cancer. This translates to a 34 percent reduction in the risk of death compared to standard of care treatment, with median survival extending from 24 months to 28 months. The outcome exceeded expectations significantly, as most analysts had anticipated a hazard ratio of 0.70, or a 30 percent reduction, as the benchmark for success.
Bernstein Senior Analyst Rebecca Liang, speaking from Bloomberg's Hong Kong studio, described the results as a surprise to the entire medical and investor community. She emphasized that the drug represents brand new biology formed around the PD-1-VEGF mechanism, which separates ivonescimab from previous standalone VEGF agents. The dual-targeting approach activates the immune system while simultaneously cutting blood supply to tumors, offering a fundamentally different mechanism of action compared to existing therapies.
However, important questions remain about the global applicability of the results. The Harmony 6 trial was conducted entirely with a Chinese patient population, which included younger patients, excluded those above age 75, and predominantly included men. A separate global trial, Harmony 3, is currently underway and will include a more diverse population with older patients and female participants. Dr. Julie Brommer, the discussant at the ASCO session, pointed out differences in patient selection criteria between the two trials, including how physicians assess risk factors such as blood vessel formation around tumors.
The commercial implications of the breakthrough are substantial. Lung cancer is the largest oncology market globally, valued at between 30 and 40 billion dollars annually. While squamous lung cancer represents a smaller subset at roughly 30 percent of all patients, the potential peak sales for ivonescimab remain significant. Liang noted that the combination possibilities between bispecific antibodies and antibody-drug conjugates could further expand the market opportunity for this new generation of therapies.
The ASCO presentation also underscores the accelerating pace of Chinese biotech out-licensing deals on the global stage. According to Liang, the first four months of 2026 have already reached close to 40 percent of last year's total deal volume, and with recent mega-deals announced, the 50 percent mark has likely been surpassed. Despite concerns about potential tightening policies affecting core intellectual property, asset-based licensing deals for individual products continue to show no signs of slowing down.
For the United States Food and Drug Administration, the path to approval will depend on the results of the Harmony 3 global trial, which enrolls a different patient population than the China-only study. The question of whether the impressive Chinese trial results can be replicated in a more diverse global cohort remains the central challenge for Acastle as it seeks to bring ivonescimab to patients worldwide. The company's chief financial officer is expected to provide further details in upcoming interviews, with investors closely watching for any updates on the global regulatory strategy.